The ARC Prize 2026 - ARC-AGI-3 is a competition that aligns with the venture's focus on AI and biotech, particularly in predicting drug resistance mutations. The competition's goal of creating an AI capable of fluid intelligence also resonates with the venture's use of ESM-2 protein language model delta-embeddings. However, the direct relevance to the venture's specific goals and the potential for funding or support are unclear.